ClinicalTrials.Veeva

Menu

Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coronary Artery Disease (IRIN)

I

Integrated University Hospital Trust of Verona

Status

Enrolling

Conditions

Coronary Microvascular Disease
Insulin Resistance
Coronary Microvascular Dysfunction

Treatments

Diagnostic Test: Hyperinsulinemic-euglycemic Clamp test
Diagnostic Test: Thermodilution based assessment of coronary microcirculation

Study type

Interventional

Funder types

Other

Identifiers

NCT06597851
IRIN (225CET)

Details and patient eligibility

About

The goal of this prospective study is to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA.

Patients with ANOCA and without diabetes will undergo invasive coronary microvascular assessment through coronary angiography and insulin resistance assessment through hyperinsulinemic-euglycemic clamp test.

Patients enrolled in the study will be followed for a period of 2 years to monitor their clinical status.

Full description

This is a prospective, experimental, single-center, explorative study designed to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA.

Patients identified as eligible for the protocol will be asked for written informed consent to participate in the study.

Participants will undergo multimodality diagnostic tests as per standard clinical practice and international recommendations:

  1. Fasting glucose, fasting insulin, HOMA index, glycated haemoglobin and oral glucose tolerance test (OGTT) will be assessed to rule out diabetes.
  2. Transthoracic echocardiography will be performed to evaluate cardiac function and cardiac remodeling.
  3. Coronary angiography will be performed to rule out obstructive CAD defined as angiographic stenosis ≥ 70% of one or more main epicardial coronary arteries (defined as vessels with diameter >2.0 mm) and/or fractional flow reserve (FFR) ≤ 0,80 as indicated by the latest European Guidelines.
  4. In case of angiographic evidence of unobstructive CAD, participants will undergo coronary microvascular function assessment using standard coronary pressure guidewire as indicated by the latest European Guidelines according to the recently described Fullphysiology method. If clinically indicated, in case of suspected epicardial or microvascular spasm, endothelial-dependent vasomotor function will be evaluated using a standard vasoreactivity test based on incremental doses of acetylcoline infusion as indicated by the latest European Guidelines.
  5. Patients will undergo hyperinsulinemic-euglycemic clamp test at Diabetology Unit of AOUI Verona to evaluate insulin resistance and the metabolic risk. In patients with no clinical concerns, adequate pharmacological washout from betablockers, ace inhibitors, sartans and/or calcium antagonists will be considered before performing the clamp test.
  6. Patients will undergo clinical follow up at 6 and 12 months via outpatient clinic or telephone contacts. Fasting glucose, fasting insulin, HOMA index and glycated haemoglobin will be re-assessed at 12 months.
  7. Transthoracic echocardiography will be repeated at 12 months.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged over 18 years.
  • Cardiac chest pain with evidence of myocardial ischemia at noninvasive myocardial stress imaging and clinical indication to diagnostic coronary angiography
  • Willing and able to give informed consent for participation in the study

Exclusion criteria

  • Obstructive CAD (defined as more than 70% luminal stenosis and/or FFR ≤0.80 in 1 or more epicardial vessels).
  • History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery.
  • Diagnosis of type II diabetes.
  • BMI ≥ 35 kg/m2.
  • Stage IV and V of chronic kidney disease (eGFR ≤ 30 ml/min, estimated through CKD - EPI Creatinine Equation).
  • Allergy or other contraindication to iodinated contrast and/or gadolinium and/or adenosine.
  • Chronic resting O2 saturation ≤ 85%.
  • Pregnancy or suspected pregnancy.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

Non-diabetic patients with ANOCA
Experimental group
Description:
* Thermodilution based assessment of coronary microcirculation with the derivation of CFR and IMR * Hyperinsulinemic euglycemic clamp for insulin resistance assessment
Treatment:
Diagnostic Test: Thermodilution based assessment of coronary microcirculation
Diagnostic Test: Hyperinsulinemic-euglycemic Clamp test

Trial contacts and locations

1

Loading...

Central trial contact

Natascia Antonioli

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems